Schizophrenia

Did you know that schizophrenia affects more than 1 percent of the world's population? See NARSAD Grants at work on the latest schizophrenia research

Schizophrenia is a severe, chronic, and generally disabling brain and behavior disorder. It is most accurately described as a psychosis - a type of illness that causes severe mental disturbances that disrupt normal thoughts, speech, and behavior. Schizophrenia is believed to be caused by a combination of genetic and environmental factors.

Positive symptoms may include delusions, thought disorders, and hallucinations. People with schizophrenia may hear voices other people don't hear, or believe other people are reading their minds, controlling their thoughts, or plotting to harm them. Negative symptoms may include avolition (a lack of desire or motivation to accomplish goals), lack of desire to form social relationships, and blunted affect and emotion. Cognitive symptoms involve problems with attention and memory, especially in planning and organization to achieve a goal. Cognitive deficits are the most disabling for patients trying to lead a normal life.

Schizohrenia research & FAQs


Visit the Schizophrenia Research Forum, fully sponsored by the Brain & Behavior Research Foundation—a virtual community of scientists collaborating in their quest for causes, improved treatments, and better understanding of schizophrenia.

Visit the Schizophrenia Research Forum for more information about research

Jeffrey A. Lieberman, M.D., Columbia University Medical Center
Jeffrey A. Lieberman, M.D.
February 07, 2012

Scientific Council Member, Jeffrey A. Lieberman, M.D. of Columbia University Medical Center presents an overview of the current state of mental healthcare, offering specific recommendations on how to continue to improve...

Herbert Y. Meltzer, M.D. discovers clozapine works for treatment-resistant schizophrenia patients and to help reduce suicide
Herbert Y. Meltzer, M.D.
January 27, 2012

In 1989 NARSAD Distinguished Investigator and Foundation Scientific Council member, Herbert Y. Meltzer, M.D., proved that the drug Clozapine(tm) can be used on patients with severe treatment-resistant schizophrenia....

Bita Moghaddam, PhD
Bita Moghaddam, PhD
January 20, 2012

Scientific Council Member Bita Moghaddam, PhD, led adolescent brain research at the University of Pittsburgh that identified more activity in teen brains, in the dorsal striatum, in response to ‘happy chemicals’ released...

Eric R. Kandel, M.D.
Eric R. Kandel, M.D.
January 19, 2012

Imagine that you are standing on a busy city street corner and you gather together the first 100 passersby who are precisely 70 years old. “In this randomly selected group, let’s assume that men and women are equally...

Paola Dazzan, M.D., Institute of Psychiatry, King’s College London
Paola Dazzan, M.D.
January 19, 2012

Paola Dazzan, M.D., who leads early psychosis research at the Institute of Psychiatry, King’s College London, has pursued the goal of applying neuroimaging to the study of psychosis with support from three NARSAD Grants....

Pages

Subscribe to